All In Biotech

Drug Trial Radar · NCT06422117

Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate to Severe Central Neuropathic Pain in China

Last checked: Nov 20, 2026Latest source record: May 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 408 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

408

Planned (sponsor's estimate)

Start

May 30, 2024

Primary completion

Jul 30, 2027

Study completion Aug 7, 2027

Sponsor

Sponsor type
Industry
First posted
May 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of HSK16149 capsule in the treatment of moderate to severe central neuropathic pain compared with placebo.

Conditions

  • Central Neuropathic Pain

Interventions

  • HSK16149 20mg-40mg BIDDrug

    Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;

  • PlaceboDrug

    Placebo, oral, 2 capsules twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The changes of pain scores after treatment in HSK16149 group and placebo group were compared with baselineTime frame: week12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.